Pulse Biosciences (Nasaq:PLSE) announced today that it appointed Jon Skinner as CFO, effective Feb. 3, 2025.
Skinner joins the developer of pulsed field ablation (PFA) technology with significant financial experience across the healthcare sector. Most recently, he served as VP, FP&A and investor relations at Copeland, a private equity-backed industrial company.
“I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecond PFA technology platform,” said Paul LaViolette, Pulse Biosciences’ new co-chair and CEO. “Jon will be a fantastic addition to our leadership team and we look forward to benefitting from his strategic and financial insights as we scale commercialization and our operations.”
Prior to Copeland, Skinner held hte post of VP, finance and corporate development at Imperative Care, a stroke care technology developer. There, he spearheaded M&A, strategy, partnership and sales operations along with providing financial and strategic support.
While at Imperative Care, Skinner also served as interim CFO of Kandu Health during its spinout and fundraising process. Other financial roles included stints at Teleflex and Axalta Coating Systems.
He joins Pulse at an “exciting point” as it progresses its nanosecond pulsed field ablation (nsPFA) technology for treating AFib.
“I believe nanosecond PFA will be a disruptive catalyst to advance the treatment of several disease states representing very large markets. I look forward to working alongside this talented and experienced management team and leveraging my experience to drive disciplined growth and operational excellence,” Skinner said.